Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.70 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24459149 | 1.00 | BACE1 (0.70) | BACE1OPRM1OPRK1OPRL1IDO1 | |
| SCHEMBL30536706 | 1.00 | BACE1 (0.70) | BACE1OPRM1OPRK1OPRL1IDO1 | |
| SCHEMBL26312575 | 1.00 | BACE1 (0.70) | BACE1OPRM1OPRK1OPRL1IDO1 | |
| SCHEMBL24453861 | 0.99 | BACE1 (0.69) | BACE1OPRM1OPRK1OPRL1IDO1 | |
| Hydrochloric Acid SCHEMBL30536654 | 0.99 | BACE1 (0.69) | BACE1OPRM1OPRK1OPRL1IDO1 | |
| Hydrochloric Acid SCHEMBL27034765 | 0.99 | BACE1 (0.69) | BACE1OPRM1OPRK1OPRL1IDO1 | |
| SCHEMBL30536656 | 0.90 | BACE1 (0.58) | BACE1OPRM1OPRK1OPRL1IDO1 | |
| SCHEMBL30799038 | 0.90 | BACE1 (0.58) | BACE1OPRM1OPRK1OPRL1IDO1 | |
| SCHEMBL30798920 | 0.88 | BACE1 (0.56) | BACE1OPRM1OPRK1OPRL1IDO1 | |
| SCHEMBL30799187 | 0.88 | BACE1 (0.58) | BACE1OPRM1OPRK1OPRL1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2023177854-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED SPIROOXINDOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295175-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED SPIROOXINDOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295175-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED SPIROOXINDOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023107417-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230174542-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174542-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230159546-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159546-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230151019-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-11384090-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11352363-B1 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| WO-2022109360-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109363-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220162216-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220162217-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220162231-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| EP-4001279-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11339170-B1 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11325916-B1 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151019-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | BACE1 3705/4885OPRM1 2320/4885OPRK1 437/4885 |
| US-11384090-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, REN | BACE1 3173/4885OPRM1 2568/4885OPRK1 649/4885 |
| US-20230159546-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, REN | BACE1 3926/4885OPRM1 2709/4885OPRK1 636/4885 |
| US-20230295175-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED SPIROOXINDOLE DERIVATIVES | ACE2, ACE, REN | BACE1 1644/4885OPRM1 2223/4885OPRK1 940/4885 |
| US-11325916-B1 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | BACE1 2982/4885OPRM1 2003/4885OPRK1 410/4885 |
| US-11339170-B1 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | BACE1 2982/4885OPRM1 2003/4885OPRK1 410/4885 |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | BACE1 2982/4885OPRM1 2003/4885OPRK1 410/4885 |
| US-20230174542-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ACE, SARS1, ACE2 | BACE1 1975/4885OPRM1 2424/4885OPRK1 1339/4885 |
| US-20220162216-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, REN | BACE1 3739/4885OPRM1 2716/4885OPRK1 625/4885 |
| US-20220162217-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, REN | BACE1 3833/4885OPRM1 2922/4885OPRK1 934/4885 |
| US-20220162231-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | BACE1 3705/4885OPRM1 2320/4885OPRK1 437/4885 |
| US-11352363-B1 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, REN | BACE1 3235/4885OPRM1 2686/4885OPRK1 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.